Evidence for a role of prostaglandins in the antepartum release of relaxin in the pregnant rat.
The relationship of the antepartum elevation in serum relaxin levels in pregnant rats to luteolysis was examined by determining the effects of the luteolysin prostaglandin F2 alpha (PGF2 alpha) and the prostaglandin synthetase inhibitor indomethacin on antepartum serum relaxin levels, as well as on luteolysis and birth. Intravenous administration of PGF2 alpha on the morning of Day 20 elevated serum relaxin levels approximately fourfold within 15 min. Administration of the prostaglandin synthetase inhibitor indomethacin from Day 19 until Day 23 protracted luteolysis, delayed or prevented birth, and delayed the antepartum elevation of serum relaxin levels, until after indomethacin treatment had been terminated. Collectively, these results indicate that prostaglandins, in particular PGF2 alpha, may promote the antepartum increase in serum relaxin levels, as well as luteolysis and birth in rats.
D000818:Animals; D003338:Corpus Luteum / Q000378:metabolism; D016861:Cyclooxygenase Inhibitors; D015237:Dinoprost; D005260:Female; D005865:Gestational Age; D007213:Indomethacin / Q000494:pharmacology; D007743:Labor, Obstetric / Q000187:drug effects; D011247:Pregnancy; D011270:Pregnancy, Animal; D011374:Progesterone / Q000097:blood; D011453:Prostaglandins / Q000502:physiology*; D011460:Prostaglandins F / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012065:Relaxin / Q000378:metabolism*
D016861:Cyclooxygenase Inhibitors; D011453:Prostaglandins; D011460:Prostaglandins F; D011374:Progesterone; D012065:Relaxin; D015237:Dinoprost; D007213:Indomethacin